Carter Cliff comes across, to nearly all who meet him, as a humble and soft-spoken scientist. You would never guess that he is a high-geared businessman who has raised over $200 million for the entities that he is a part of.
This podcast is useful for biotech founders because you’ll hear the story of how Carter was able to penetrate the world of venture funding without being overly self-promotional. And in fact, it is his humility that was perhaps the largest contributor to his success in achieving this.
You’ll also hear practical tips and advice for biotech founders, such as:
What originally attracted him to stem cell research
The workaround he had to create due to lack of a venture fund to support his entities
The capital efficient way to develop a company early on
How he raised $230MM in venture funding
Where to find a good venture capital firm
Why alignment of interests matters so much in getting funded
What he loves most about building companies
Carter Cliff is the CEO of Papillon Therapeutics. Papillon is advancing genetic medicines for life threatening conditions including Cystinosis, Friedreich's ataxia, Danon disease, and Alzheimer's disease, and the company is currently partnered with Novartis on a phase 1/2 trial for their lead candidate in cystinosis. Carter has a multi-decade career in biotech and life sciences and is also a venture partner at Saisei Ventures where he helps launch biotechnology companies, and has raised over $200MM in funding across various ventures.
Enjoy the show!
Disclaimers
The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.
Comments